Patient derived xenograft (PDX) is defined as a growth of patients’ tumor in the xenograft setting. The evolution of cancer model in animal has a century old history. The most single reason that exerted the pressure ...Patient derived xenograft (PDX) is defined as a growth of patients’ tumor in the xenograft setting. The evolution of cancer model in animal has a century old history. The most single reason that exerted the pressure on the traditional animal model of cancer to evolve to PDX is that the traditional models have not delivered as expected and traditional models have not predicted clinical success. In spite of well above 50 drugs developed and approved for oncology over the last several decades, there remains a nirking paucity of clinical success as a reminder that this war on cancer riding on the animal model is far from won. In a backbreaking attempt to analyze the failure, the limitation of the “model” system appeared to be the most rational cause of this shortcoming. It was more of a failure to test a drug rather than a failure to make a drug that stunted our collective growth and success in cancer research. PDX is the product of this age-old failure and its fitness is currently tested in virtually all organ-type solid tumors. This review will present and appraise PDX model in the context of its evolution, its future promise, its limitations and more specifically, the current content of PDX in different solid tumors including breast, lung, colorectal, prostrate, GBM, pancreatic, hepatocellular carcinoma and melanoma.展开更多
目的:评价实体瘤中心变性粉碎引流术(the method of solid tumors center’s denaturation,smashing and drainage,TCDSD)的疗效及安全性。方法:采用腹水型Walker 256乳腺癌细胞接种雄性SD大鼠腋下形成实体瘤模型,分别设模型对照组(A组...目的:评价实体瘤中心变性粉碎引流术(the method of solid tumors center’s denaturation,smashing and drainage,TCDSD)的疗效及安全性。方法:采用腹水型Walker 256乳腺癌细胞接种雄性SD大鼠腋下形成实体瘤模型,分别设模型对照组(A组)、实体瘤中心热变性组(B组)、热变性+中心粉碎+引流(TCDSD)组(C组)、TCDSD后粉碎腔内阿霉素和预知子种子醇提物复合给药组(D组)。分别予相应干预,并分析各组大鼠肿瘤生长及肿瘤空腔重构情况,比较大鼠荷瘤体质量及对肝、肾、脾的影响。结果:瘤质量见C组<D组<B组<A组的趋势;抑瘤率见C组>D组>B组的趋势;C、D组大鼠肿瘤粉碎腔均被肿瘤及变性后肿瘤组织填满,实现术区重构;各组大鼠荷瘤体质量、去瘤体质量、肝肾脾质量差异均无统计学意义(P>0.05),肝肾脾外观无明显差别,提示各治疗组均未见毒副作用。结论:TCDSD治疗实体瘤安全有效,是对完善和优化现有肿瘤治疗方案的积极探索。展开更多
文摘Patient derived xenograft (PDX) is defined as a growth of patients’ tumor in the xenograft setting. The evolution of cancer model in animal has a century old history. The most single reason that exerted the pressure on the traditional animal model of cancer to evolve to PDX is that the traditional models have not delivered as expected and traditional models have not predicted clinical success. In spite of well above 50 drugs developed and approved for oncology over the last several decades, there remains a nirking paucity of clinical success as a reminder that this war on cancer riding on the animal model is far from won. In a backbreaking attempt to analyze the failure, the limitation of the “model” system appeared to be the most rational cause of this shortcoming. It was more of a failure to test a drug rather than a failure to make a drug that stunted our collective growth and success in cancer research. PDX is the product of this age-old failure and its fitness is currently tested in virtually all organ-type solid tumors. This review will present and appraise PDX model in the context of its evolution, its future promise, its limitations and more specifically, the current content of PDX in different solid tumors including breast, lung, colorectal, prostrate, GBM, pancreatic, hepatocellular carcinoma and melanoma.
文摘目的:评价实体瘤中心变性粉碎引流术(the method of solid tumors center’s denaturation,smashing and drainage,TCDSD)的疗效及安全性。方法:采用腹水型Walker 256乳腺癌细胞接种雄性SD大鼠腋下形成实体瘤模型,分别设模型对照组(A组)、实体瘤中心热变性组(B组)、热变性+中心粉碎+引流(TCDSD)组(C组)、TCDSD后粉碎腔内阿霉素和预知子种子醇提物复合给药组(D组)。分别予相应干预,并分析各组大鼠肿瘤生长及肿瘤空腔重构情况,比较大鼠荷瘤体质量及对肝、肾、脾的影响。结果:瘤质量见C组<D组<B组<A组的趋势;抑瘤率见C组>D组>B组的趋势;C、D组大鼠肿瘤粉碎腔均被肿瘤及变性后肿瘤组织填满,实现术区重构;各组大鼠荷瘤体质量、去瘤体质量、肝肾脾质量差异均无统计学意义(P>0.05),肝肾脾外观无明显差别,提示各治疗组均未见毒副作用。结论:TCDSD治疗实体瘤安全有效,是对完善和优化现有肿瘤治疗方案的积极探索。
